Drug

Alemtuzumab

Approved · EMA

Emerging researchLate-stage development

Also known as Campath, Lemtrada.

RxNorm117055UNII3A189DH42V

Research papers

Active clinical trials

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Autologous Stem Cell Transplantation With CD34-Selected Peripheral Blood Stem Cells (PBSC) in Patients With Treatment Resistant Systemic Sclerosis (SSc)

Clinical trial2026-08-01Primary completion · ClinicalTrials.gov

T-Cell Depleted, Alternative Donor Transplant in Pediatric and Adult Patients With Severe Sickle Cell Disease (SCD) and Other Transfusion-Dependent Anemias

Clinical trial2026-08-01Primary completion · ClinicalTrials.gov

Clinical trial2026-07-13Results expected Q2 2032 · ClinicalTrials.gov

Haploidentical Transplant for Patients With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide

Clinical trial2026-07-08Results expected Q2 2034 · ClinicalTrials.gov

High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease

Clinical trial2026-07-08Results expected Q4 2027 · ClinicalTrials.gov

Phase I/II Study of Allogeneic Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease (SCD)

Clinical trial2026-07-08Results expected Q3 2028 · ClinicalTrials.gov

CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease

Clinical trial2026-07-01Primary completion · ClinicalTrials.gov

Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation in Non-Malignant Diseases

Clinical trial2026-06-12Results expected Q3 2028 · ClinicalTrials.gov

Open-label, Single-Center, Phase 1 Study to Estimate the Minimum Effective Dose (MED) of 131I-apamistamab for Non-myeloablative Conditioning in Patients With Severe Sickle Cell Disease

Clinical trial2026-06-10Results expected Q1 2030 · ClinicalTrials.gov

Approval: Lemtrada (EMA)

Regulatory2013-09-12EMA

Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.

Research2008-10-01Cancer

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab.

Research2008-06-27Leukemia research

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Alemtuzumab

Aliases & brands

CampathLemtrada

RxNorm CUI

117055

UNII

3A189DH42V

Regulatory jurisdictions

ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval

2013-09-12

Latest approval

2013-09-12

Authorities

EMA

Total events

emaEuropean Medicines Agency· 1 event

2013-09-12Approval

Approval: Lemtrada (EMA)

Indication: Lemtrada is indicated for adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.